Delivering a biologic to the market can be a challenging, financially demanding and time-consuming process. Robust safety data, timely reporting and rigorous attention to quality and detail are critical factors in the successful development of a biologic. Charles River Biopharmaceutical Services (BPS) delivers client-focused solutions for the specific testing and manufacturing requirements of your biologic.
BPS follows international regulatory guidelines for testing and clinical-scale manufacturing of biologics. The assays provided range from cell characterization and process validation studies through to stability and product release testing. Manufacturing services include cell banking, storage, fill and finish, and viral vaccine and antisera production.
Our global footprint includes sites in both Erkrath and Cologne, Germany; Malvern, PA; Wilmington, MA; Edinburgh, UK; and Ballina, Co. Mayo, Ireland. Furthermore, to address the growing Asian market, BPS has agents in Australia (JDJ Bioservices), Japan (LSG Corporation), India (Zelle Biotechnology Private Limited), Korea (Sartorius Korea Biotech), Singapore [Biomedical Research and Support Services (BRASS™)] and Taiwan (LifeOptimal Technology, Inc.). As a global organization, BPS can provide you with more flexibility, experience and expertise in multiple regulatory environments to accelerate the development of your biologic, enabling you to get your product to market faster.
early-stage biopharmaceutical manufacturing services